Relief Therapeutics Announces Final Readout of PKU GOLIKE Clinical Trial
Clinical Trial Demonstrates Superior Metabolic Control During Prolonged Fasting in PKU PatientsResults Expected to Promote Awareness and Adoption of PKU...
Brain
How Popular Weight Loss Drugs Are Reshaping Holiday Feasts
Dr. Michael Koehler, Medical Director at Affinity Whole Health, offers tips ahead of the holiday season. VALLEY VIEW, OH /...
Yale Neurosurgeon Dr. Patrick F. Doherty: Where Surgical Excellence Meets Compassionate Care
A Profile of Innovation and Patient-Centered Neurosurgery at Yale Medicine NEW HAVEN, CONNECTICUT / ACCESSWIRE / December 13, 2024 /...
Medicenna Presents Preclinical Data on MDNA11 as First Step to Shrink Tumors Before Surgery and Prevent Metastasis at the 2024 San Antonio Breast Cancer Symposium (SABCS)
Single-agent MDNA11 was more effective than a combination of immune checkpoint inhibitors (anti-mPD1 and anti-mCTLA4) in preventing metastasis and achieving...
SOUP AI Platform Launches Crowdfunding Campaign
Charlotte, North Carolina--(Newsfile Corp. - December 12, 2024) - SOUP, the first fully AI-driven social platform, transforming idea-sharing and collaboration,...
Healthcare Executives Embrace Generative AI to Boost Patient Outcomes
Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Dec. 12, 2024 /PRNewswire/ -- USA News Group News Commentary – The...
Cellev8 Nutrition Launches the First GLP1 Support Gummy With Clinically Tested Ingredients
CELLEV8 Launches First Post-GLP-1 Gummy Supplement: "SlimCell™" with Clinically Proven Ingredients to Compliment GLP-1 WELLINGTON, FL / ACCESSWIRE / December...
iTeos Therapeutics Presents Interim A2A-005 Clinical Trial Data, Translational, and Preclinical Data from Inupadenant at ESMO Immuno-Oncology Congress
- Inupadenant + carboplatin/pemetrexed in Phase 2 A2A-005 trial demonstrated a 63.9% overall response rate (ORR) and a median PFS...
BrainsWay Reports Positive Independent Pilot Data on Accelerated Deep TMS Treatment of Alcohol Use Disorder
BURLINGTON, Mass. and JERUSALEM, Dec. 12, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
2024 Design Intelligence Award Held at China Academy of Art, Hangzhou, China
HANGZHOU, China, Dec. 12, 2024 /PRNewswire/ -- The ceremony for the 2024 Design Intelligence Award (DIA) took place on December...
Medical Gas Blenders Market to Grow by USD 582 Million (2024-2028), Driven by Aging Population and Chronic Diseases, with AI Impacting Market Trends – Technavio
NEW YORK, Dec. 11, 2024 /PRNewswire/ -- Report on how AI is redefining market landscape - The global medical gas blenders...
Carolina ranks 9th among all top U.S. research institutions
CHAPEL HILL, N.C., Dec. 11, 2024 /PRNewswire/ -- Research spending at Carolina has topped $1.55 billion, fueling the state's economy,...
AARP Showcases Pioneering AgeTech Innovations at CES 2025
New AARP CEO Dr. Myechia Minter-Jordan to Discuss Innovations Shaping the Future of Aging and Well-Being WASHINGTON, Dec. 11, 2024...
Hockey Star Max Domi Teams Up with Aires Tech as the Newest #AiresAthletes Ambassador and Brand Partner
Domi strengthens the #AiresAthletes campaign, reinforcing the importance of protection from EMF radiation to enhance recovery and overall well-being* Domi...
Therma Bright Congratulates Investment Partner Inretio’s Promising Initial Results from PREVA(TM) Device’s First Clinical Phase
Inretio presents initial clinical trial results at prestigious BRAIN Conference 2024 in London.Toronto, Ontario--(Newsfile Corp. - December 11, 2024) -...
Gain Therapeutics To Present At Biotech Showcase 2025
Presentation to Feature Lead Drug Candidate GT-02287 and Magellan Drug Discovery PlatformBETHESDA, Md., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Gain...
Results from Social Listening Analysis and Survey of People with Narcolepsy Uncover Real-Life Challenges with Twice-Nightly Oxybate Therapy
– Findings published in Brain Sciences showed missed doses and potential for injury when waking to take a second dose...
BriaCell Presents Unprecedented Overall Survival Data in Metastatic Breast Cancer in Spotlight Poster at 2024 SABCS®
Median overall survival (OS) to date of 13.4 months for Phase 2 patients treated with the Phase 3 formulation (15.6...
Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial for Obesity Currently Enrolling with U.S. Patient Cohort to be Added in 2025. Scilex Bio Reports Positive Results from the Recently Completed Phase 1 Trials Conducted by NeuroBiogen for KDS2010, a Novel Oral Tablet Recently Synthesized Potent, Selective, and Reversible Monoamine Oxidase B inhibitor
The ongoing obesity Phase 2 trial is a randomized, double-blind, placebo-controlled, dose finding, clinical trial to evaluate the safety and...
HMNC Brain Health Collaborates with the Austrian Institute of Technology and the Danube Private University to Win Grant from the Austrian Research Promotion Agency
Grant for "Personalized Medicine Enabled by Intelligent Sensing Systems” ProjectMUNICH, Dec. 11, 2024 (GLOBE NEWSWIRE) -- HMNC Brain Health, a...